Zacks: Analysts Expect MediWound Ltd. (MDWD) Will Announce Quarterly Sales of $740,000.00
Wall Street brokerages forecast that MediWound Ltd. (NASDAQ:MDWD) will announce sales of $740,000.00 for the current quarter, according to Zacks. Three analysts have provided estimates for MediWound’s earnings. The lowest sales estimate is $600,000.00 and the highest is $820,000.00. MediWound reported sales of $520,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 42.3%. The company is scheduled to report its next quarterly earnings report on Monday, November 13th.
On average, analysts expect that MediWound will report full year sales of $740,000.00 for the current financial year, with estimates ranging from $2.50 million to $3.40 million. For the next fiscal year, analysts anticipate that the company will report sales of $8.70 million per share, with estimates ranging from $5.80 million to $11.00 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for MediWound.
MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The business had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.69 million. During the same period last year, the business posted ($0.34) EPS. MediWound’s revenue was up 93.8% on a year-over-year basis.
A number of research analysts recently commented on MDWD shares. Jefferies Group LLC set a $10.00 price target on MediWound and gave the company a “buy” rating in a report on Friday, August 25th. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a report on Monday, June 26th. Cowen and Company started coverage on MediWound in a report on Thursday, September 28th. They issued an “outperform” rating and a $9.00 price target for the company. Zacks Investment Research downgraded MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, ValuEngine downgraded MediWound from a “sell” rating to a “strong sell” rating in a report on Friday, September 22nd. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $9.15.
Shares of MediWound (MDWD) opened at 5.10 on Friday. The stock’s 50 day moving average price is $5.75 and its 200 day moving average price is $6.44. MediWound has a 12 month low of $4.25 and a 12 month high of $8.25. The firm’s market cap is $111.97 million.
TRADEMARK VIOLATION NOTICE: This article was posted by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/06/zacks-analysts-expect-mediwound-ltd-mdwd-will-announce-quarterly-sales-of-740000-00.html.
A number of institutional investors and hedge funds have recently modified their holdings of MDWD. Wellington Management Group LLP raised its stake in MediWound by 11.0% during the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in MediWound by 20.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares in the last quarter. Renaissance Technologies LLC raised its stake in MediWound by 1.7% during the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in MediWound by 23.5% during the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock valued at $447,000 after buying an additional 12,522 shares in the last quarter. 19.55% of the stock is owned by hedge funds and other institutional investors.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.